Lilie's 2026 Rice Innovation Fellows. Photo via LinkedIn

Editor's note: As fall reaches full swing, Houston's innovation scene is calling on the latest batch of founders and startups looking to make a difference. A number of accelerators have opened applications. Read below to see which might be a good fit for you or your venture. And take careful note of the deadlines. Please note: this article may be updated to include additional information and programs.

Did we miss an accelerator or competition accepting applications? Email innoeditor@innovationmap.com for editorial consideration.

Texas Life Science Forum

Deadline: Oct. 2

Details: Ventures can apply to present at the 15th annual Texas Life Science Forum, hosted by BioHouston and Rice Alliance. Participants will meet during office hours with venture capitalists, tech scouts, corporate venture groups and angel investors, and present their pitches in a public forum. Pitches take place on Nov. 10 and office hours are held Nov. 11. Find more information here.

Greentown Lab's Go Make 2027: Advanced Carbon Materials with ExxonMobil

Deadline: Oct. 9

Details: Greentown Labs is seeking applications from startups developing novel carbon-based technologies for its latest Go Make cohort in conjunction with ExxonMobil. The structured accelerator is designed to facilitate validation activities and explore potential long-term collaborations with Exxon, according to Greentown. Founders will have the opportunity to engage directly with industry leaders to test, validate and scale their carbon technologies in real commercial contexts. The program tentatively starts on Jan. 20, 2027 and concludes June 16, 2027. Find more information here.

Activate's U.S. Fellowship Cohort 2027

Deadline: Oct. 30

Details: Activate supports scientists at "the outset of their entrepreneurial journey." It partners with U.S.-based funders and research institutions to support its fellows in developing high-impact technology. Its fellows receive a living stipend, research and development funding, connections from Activate's robust network of mentors and access to a curriculum specific to the program for two years. Applicants must have a bachelor’s degree and 4-plus years of post-baccalaureate scientific research, engineering or technology development experience. Their work must be based in the physical or biological sciences or related engineering disciplines. Find more information here.

Rice Innovation Fellows

Deadline: Oct. 30

Details: The Liu Idea Lab for Innovation and Entrepreneurship (Lilie)'s Rice Innovation Fellows program supports Rice Ph.D. students and postdocs in turning their research into real-world ventures. Participants receive $10,000 in translational research funding, co-working space and personalized mentorship. Candidates from all Rice engineering and science-related disciplines are encouraged to apply. Find more information here.

The TMC's Accelerator for Cancer Therapeutics

Deadline: Oct. 30

Details: Texas-based ventures and researchers developing a cancer therapeutics project can apply to this accelerator funded by the Cancer Prevention and Research Institute of Texas. The nine-month program runs February-September 2027 and focuses on market research, FDA regulations, intellectual property, licensing, finance, fundraising, legal and other critical areas for cancer-related ventures. Participants will complete the program with at least one grant submission and have the option to pitch to investors, corporate partners, media and other influential guests. Find more information here.

CrossBridge Bio co-founder and CEO Michael Torres. Photo via LinkedIn

Eli Lilly scoops up Houston biotech startup in $300 million deal

big pharma deal

Pharmaceutical giant Eli Lilly has acquired Houston biotech startup CrossBridge Bio, which develops antibody-drug conjugates for cancer, in a deal worth up to $300 million. The deal was celebrated by TMC Venture Fund and the University of Texas Health Science Center at Houston last week.

CrossBridge, founded in 2023, is developing ADCs based on research by Kyoji Tsuchikama and Zhiqiang An, both of UT Health Houston. Tsuchikama is an associate professor of medicinal chemistry and a globally recognized ADC pioneer, and An is a professor of molecular science and vice president of drug discovery.

Antibody-drug conjugates (ADCs) are a potent combination of targeted therapy and chemotherapy that kills cancer cells while saving healthy tissue.

Clinical trials for CrossBridge’s primary ADC candidate, CBB-120, are expected to start this year, pending approval from the U.S. Food and Drug Administration (FDA).

“I’m proud of how well our team has executed and advanced our platform in such a short time since the company’s founding,” Michael Torres, co-founder and CEO of CrossBridge, said in a news release. “By becoming a part of Lilly, a leader in patient-focused therapeutic development, we are well-positioned to further accelerate the clinical potential of this approach.”

Under the Lilly deal, CrossBridge shareholders were expected to receive an upfront payment along with a follow-up payment based on the achievement of certain milestones.

In 2024, CrossBridge closed a $10 million seed round. Among the investors in CrossBridge are the Texas Medical Center Venture Fund, CE-Ventures, Alexandria Venture Investments, Portal Innovations, Linden Lake Labs, and the Cancer Prevention and Research Institute of Texas (CPRIT). It was formed in TMC Innovation’s Accelerator for Cancer Therapeutics program."Built within the TMC ecosystem, CrossBridge Bio grew with the support, funding, and resources that helped shape its trajectory. TMC led the company's early financing and watched it evolve from its earliest days to its acquisition by Eli Lilly," William McKeon, president and CEO of the Texas Medical Center, shared in a LinkedIn post. "[This is a] strong reminder that breakthrough science and the right early backing can change what’s possible."
The Cancer Prevention and Research Institute of Texas has awarded its latest round of grants. Photo via tmc.edu

4 Houston-area institutions get $8M for cancer research facilities

fighting cancer

Cancer research capabilities in the Houston area just got an $8 million boost.

On Wednesday, May 20, the Cancer Prevention and Research Institute of Texas (CPRIT) awarded $8 million in grants to institutions in Houston and Bryan for the creation or expansion of so-called “core” cancer research facilities.

“Core facilities provide shared access to advanced technology, equipment, and scientific expertise that may not be available at every institution,” CPRIT says. “These core facilities are vital to not only cancer research but also to the study of diseases beyond cancer.”

Houston-area recipients of these $2 million grants are:

  • A facility at the University of Texas Health Science Center for preclinical support of cancer researchers in Texas to evaluate new safe, effective drugs and drug combinations.
  • The Accelerator for Cancer Therapeutics, operated by Houston’s Texas Medical Center Foundation. The accelerator helps researchers and startups move innovative cancer treatments from the lab to clinical trials.
  • Rice University’s Genetic Design & Engineering Center in Houston. The center enables researchers to collaborate on studies of custom DNA for cancer treatment.
  • A facility at the Texas A&M University System’s Health Science Center in Bryan that aims to speed up the development of cancer therapies.

In addition to those grants, the University of Texas M.D. Anderson Cancer Center, Methodist Hospital Research Institute, Baylor College of Medicine, and Rice University shared $21 million to recruit cancer researchers from other institutions.

The largest of those grants—totalling $4 million—went to M.D. Anderson for the recruitment of renowned cancer researcher Andre Nussenzweig from the National Institutes of Health. His research focuses on how DNA damage and faulty DNA repairs lead to cancer.

Here are the totals for the other CPRIT grants awarded in the Houston area:

  • $12.8 million to Houston-based Indapta Therapeutics for the development of an off-the-shelf therapy that naturally kills cancer cells, combined with an immunity-targeting agent for a type of leukemia.
  • $11.1 million to MD Anderson, including $5 million for a statewide platform to improve long-term health outcomes in adolescents and young adults who survived cancer.
  • $8.4 million to Baylor College of Medicine, including $4.8 million for two training programs for cancer researchers.
  • $6.25 million to UT Health Houston, including $4 million for a biomedical informatics and genomics training program for cancer researchers.
  • $4.4 million to the Texas A&M Health Science Center’s Houston campus, including $2.4 million for a cancer therapeutics training program.
  • $2.75 million to Rice, including $250,000 for a study of ovarian cancer.
  • $2 million to Houston-based March Biosciences for the development of a targeted therapy for treating T-cell lymphoma.
  • $1.15 million to the University of Houston, including $900,000 for a platform for detection of lung cancer.
  • $900,000 to Texas A&M in Bryan to conduct clinical drug trials in rural and underserved communities around the state.
  • $800,000 to Houston- and Israel-based Xerient Pharma for the development of an oral form of a cell-protecting drug called amifostine to protect the upper GI tract from radiation damage during pancreatic cancer treatment.
  • $659,000 to Missouri City-based OmniNano Pharmaceuticals for the development of a two-drug combination to treat the most common form of pancreatic cancer.
  • $250,000 to the University of Texas Medical Branch at Galveston for a novel therapeutic to prevent colitis-related colorectal cancer.
Innovators in immunotherapy, precision drug discovery, monoclonal antibodies, and diagnostic and therapeutic technologies have joined TMC's Accelerator for Cancer Therapeutics. Photo courtesy TMC.

TMC names 2025 cohort of cancer treatment innovators

ready to grow

Texas Medical Center Innovation has named more than 50 health care innovators to the fifth cohort of its Accelerator for Cancer Therapeutics (ACT).

The group specializes in immunotherapy, precision drug discovery, monoclonal antibodies, and diagnostic and therapeutic technologies, according to a statement from TMC.

During the nine-month ACT program, participants will enjoy access to a network of mentors, grant-writing support, chemistry resources, and the entrepreneur-in-residence program. The program is designed to equip participants with the ability to secure investments, develop partnerships, and advance the commercialization of cancer therapeutics in Texas.

“With over 35 million new cancer cases predicted by 2050, the urgency to develop safer, more effective, and personalized treatments cannot be overstated,” Tom Luby, chief innovation officer at Texas Medical Center, said in a news release.

Members of the new cohort are:

  • Alexandre Reuben, Kunal Rai, Dr. Cassian Yee, Dr. Wantong Yao, Dr. Haoqiang Ying, Xiling Shen, and Zhao Chen, all of the University of Texas MD Anderson Cancer Center
  • Dr. Andre Catic and Dr. Martin M. Matzuk, both of the Baylor College of Medicine
  • Cynthia Hu and Zhiqiang An, both of UTHealth Houston
  • Christopher Powala, Aaron Sato, and Mark de Souza, all of ARespo Biopharma
  • Daniel Romo, Dr. Susan Bates, and Ken Hull, all of Baylor University
  • Eugene Sa & Minseok Kim, both of CTCELLS
  • Gomika Udugamasooriya and Nathaniel Dawkins, both of the University of Houston
  • Dr. Hector Alila of Remunity Therapeutics
  • Iosif Gershteyn and Victor Goldmacher, both of ImmuVia
  • João Seixas, Pedro Cal, and Gonçalo Bernardes, all of TargTex
  • Ken Hsu and Yelena Wetherill, both of the University of Texas at Austin
  • Luis Martin and Dr. Alberto Ocaña, both of C-Therapeutics
  • Dr. Lynda Chin, Dr. Keith Flaherty, Dr. Padmanee Sharma, James Allison, and Ronan O’Hagan, all of Project Crest/Apricity Health
  • Michael Coleman and Shaker Reddy, both of Metaclipse Therapeutics
  • Robert Skiff and Norman Packard, both of 3582.ai
  • Rolf Brekken, Uttam Tambar, Ping Mu, Su Deng, Melanie Rodriguez, and Alexander Busse, all of UT Southwestern Medical Center
  • Ryan Swoboda and Maria Teresa Sabrina Bertilaccio, both of NAVAN Technologies
  • Shu-Hsia Chen and Ping-Ying Pan, both of Houston Methodist
  • Thomas Kim, Philipp Mews, and Eyal Gottlieb, all of ReEngage Therapeutics
The ACT launched in 2021 and has had 77 researchers and companies participate. The group has collectively secured more than $202 million in funding from the NIH, CPRIT and venture capital, according to TMC.
CrossBridge Bio, formed during the TMC Innovation’s Accelerator for Cancer Therapeutics program, closed a $10 million seed round led by TMC Venture Fund and CE-Ventures. Photo via Getty Images

Houston biotech startup secures $10M seed round to propel cancer-fighting therapy from bench to bedside

fresh funding

A Houston biotech company based off research out of UTHealth Houston has raised seed funding to continue developing its cancer-fighting therapeutic.

CrossBridge Bio, formed during the TMC Innovation’s Accelerator for Cancer Therapeutics program, closed a $10 million seed round led by TMC Venture Fund and Crescent Enterprises' VC arm, CE-Ventures. The round also included participation from Portal Innovations, Alexandria Venture Investments, Linden Lake Labs, and several pre-seed investors.

“We are thrilled to have the support of such experienced investors who share our vision of bringing transformative cancer therapies to patients in need,” Michael Torres, CEO of CrossBridge Bio, says in a news release. Torres served as an entrepreneur in residence of ACT.

The company is working on the next-generation of antibody-drug conjugates (ADC) therapeutics that process dual payloads as targeted treatments for a set of challenging cancers. The innovative treatment is based on research from UTHealth experts Dr. Kyoji Tsuchikama and Dr. Zhiqiang An.

“Our dual-payload ADC technology is designed to deliver synergistic therapeutic effects using highly stable linkers that ensure payload release only within the targeted cancer cells, thereby maximizing their therapeutic effectiveness while minimizing the liabilities associated with uptake in unintended tissues, as seen with many of today’s cancer treatments," Torres continues.

He explains that the funding will toward advancing CrossBridge's first development candidate, CBB-120, into preclinical non-GLP toxicology studies in addition to derisking the company’s proprietary linker technology with dual-payload applications, per the release.

As a result of the raise, William McKeon, president and CEO of the Texas Medical Center, and Damir Illich, manager of life sciences of CE-Ventures, will join CrossBridge Bio’s board of directors.

“We are proud to back CrossBridge Bio in their mission to develop the next generation of cancer therapies,” McKeon says in the release. “Their dual-payload ADCs are designed to deliver targeted drug release within cancer cells with greater stability, precision, and control. These breakthrough advancements have the potential to change patients’ lives worldwide and we look forward to helping drive their development.”

TMCi named its 2024 Accelerator for Cancer Therapeutics cohort.

TMC names 2024 cohort of cancer treatment innovators

ready to grow

For the fourth year, Texas Medical Center Innovation has named its annual cohort of Texas health tech innovators working on promising cancer therapeutics.

TMCi named its 2024 Accelerator for Cancer Therapeutics cohort last week, and the 23 Texas researchers and companies selected will undergo a nine-month program that will provide them with mentorship and programming, as well as open doors to potential investors and strategic partners.

“The ACT program provides a bridge to commercialization in Texas by surrounding innovators with strategic mentorship, milestone development, and a network of resources to move their projects forward,” Emily Reiser, associate director of TMC Innovation, says in a news release. "We are excited to welcome this year's cohort and to continue enabling participants to advance their solutions to treat cancer."

The program has accelerated 76 researchers and companies to date, many of which — like March Biosciences and Mongoose Bio — have gone on to secure $130 million in funding from venture capitalists and grant funding.

“Our program has cultivated a dynamic ecosystem where partners, researchers, and inventors, who have been part of the journey since its inception and received various forms of funding, continue to propel their life-saving products and technologies forward," Ahmed AlRawi, program manager of ACT, says in the release. "Our 2024 cohort represents our most diverse cohort to date, including eight companies led by women entrepreneurs. Additionally, we are particularly proud that the cohort includes a blend of new and recurring organizations that have leveraged this opportunity in the past to extend their work and continue the momentum to build off the successes of our previous years.”

The 2024 participants are:

  • Alexandre Reuben of UT-MD Anderson Cancer Center
  • Betty Kim & Jiang Wen of UT-MD Anderson Cancer Center
  • Bin He of Houston Methodist
  • Daniel Kiss & John Cooke of PeakRNA at Houston Methodist
  • Hongjun Liang of Texas Tech-Lubbock
  • Jacob Goell & Isaac Hilton of Mercator Biosciences at Rice University
  • Jay Hartenbach & Matthew Halpert of Diakonos Oncology Corp.
  • Kathryn O’Donnell of UT-Southwestern
  • Maralice Conacci Sorrell of UT-Southwestern
  • Neeraj Saini of UT-MD Anderson Cancer Center
  • Neil Thapar of Barricade Therapeutics Corp.
  • Nina Keshavarzi of Celine Biotechnologies
  • Raphael G. Ognar & Henri Bayle of NKILT Therapeutics Inc.
  • Richard Austin & Michael Abrahamson of Reglagene Inc.
  • Tim Peterson & Joppe Nieuwenhuis of Bioio Inc.
  • Todd Aguilera & Eslam Elghonaimy of UT-Southwestern
  • Venkata Lokesh Battula of Siddhi Therapeutics Inc. at UT-MD Anderson Cancer Center
  • Weei-Chin Lin & Fang-Tsyr Lin of Baylor College of Medicine
  • Yong Li & Dongxiao Feng of Sotla Therapeutics at Baylor College of Medicine
  • Anil Sood & Zhiqiang An of UT-MD Anderson Cancer Center
  • Narendra Kumar & Jayshree Mishra of Texas A&M-College Station
  • Tao Wang of NightStar Biotechnologies Inc. at UT-Southwestern
  • Jian Hu of UT-MD Anderson Cancer Center
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Meet the 40+ finalists for the 2026 Houston Innovation Awards

The Top Startups

Editor's note: We are just days away from unveiling the winners of the 2026 Houston Innovation Awards. Before the big reveal, we've compiled all of the coverage of this year's finalists. Get to know the 40+ finalists for nine awards categories below, then stay tuned to InnovationMap.com, where we'll announce the winners on Wednesday, November 18.

Minority-founded Business Finalists 

Our Minority-founded Businesses category honors innovative Houston startups founded or co-founded by BIPOC or LGBTQ+ representation. Five minority-founded businesses have been named finalists for the 2026 award. The finalists range from an AI edtech startup to a company operating in the floating offshore energy infrastructure sector.

They are: AI Made Fun, Deep Anchor Solutions, HEXASpec, Prana Surgical, and Torres Orbital Mining Inc. Read more.

Female-founded Business Finalists

Houston is home to many standout female founders, making inroads and breakthroughs in every industry. Our Female-founded Business category honors women-led startups that are shaping Houston innovation. Five female-founded businesses have been named finalists for the 2026 award. The finalists range from an AI startup for C-Suite execs to a company developing semi-autonomous crawler robots for corrosion detection.

They are: Adair, ARIX Technologies, Bairitone Health, FlowCellutions, and ParaDocs Health. Read more.

Health Tech Business Finalists

Houston has been driving medical innovation for decades and the local healthcare ecosystem continues to improve how patients are diagnosed, treated and cared for. The Health Tech Business category in our 2026 Houston Innovation Awards honors innovative startups within the health and medical technology sectors. Four forward-thinking businesses have been named finalists for the 2026 award. This year's finalists range from a startup developing miniaturized medical technologies for space to a company using AI to help develop cancer treatment plans.

They are: Bairitone Health, InformAI Inc., Prana Surgical, and Skybound MedTech. Read more.

Deep Tech Business Finalists

Houston has long been at the forefront of innovation, from NASA’s Johnson Space Center to its startup ecosystem using technology to disrupt industries. Our Deep Tech Business category honors innovative startups providing technology solutions based on substantial scientific or engineering challenges, including those in the AI, robotics and space sectors. Five deep tech companies have been named finalists for the 2026 award.

They are: Casimir, FocisAI, Machine Saver Inc., Square Robot, and Venus Aerospace. Read more.

Energy Transition Business Finalists

Houston is home to a growing number of startups reshaping what it means to be called the "Energy Capital of the World." Our Energy Transition Business category honors those innovative startups that are providing solutions within renewables, climatetech, clean energy, alternative materials, circular economy, and more. Five clean energy startups have been named finalists for the 2026 award. The finalists range from a lower-emission steel producer to a diagnostics platform developer working to support batteries used in data centers.

They are: Capwell Services, FlowCellutions, Hertha Metals, Mars Materials, and Solidec. Read more.

Scaleup of the Year Finalists

From IPOs to groundbreakings, some of Houston's most innovative companies reached major milestones this year. Our Scaleup of the Year category honors innovative later-stage startups that have recently reached a significant milestone in company growth. Three scaleups have been named finalists for the 2026 award.

They are: Erock, Hertha Metals, and Venus Aerospace. Read more.

Incubator/Accelerator of the Year Finalists

It takes a village to launch a business. That's where Houston's network of incubators and accelerators can step in, providing the resources, mentorship and community needed to push a fledgling company forward. Our Incubator/Accelerator of the Year category honors local organizations that are championing and fueling the growth of Houston startups. Three incubators and accelerators have been named finalists for the 2026 award. They support startups ranging from hard-tech companies to food and youth concepts.

They are: Activate, Impact Hub Houston, and MarMo Innovation. Read more.

Startup of the Year Finalists

Seven exceptional finalists are in the running for the title of Startup of the Year, which is our people's choice award in the annual Houston Innovation Awards. From innovative platforms benefiting the education, commerce, health, investment and IT sectors to next-gen memory technology and improvements for robotic supply chains, these startups are making an impact in Houston and beyond.

The finalists are: Fluxworks, IronLattice, Lumino, Progress Report, Rosarium Health, TokenRoster, and Thread. Read more.

Mentor of the Year Finalists

Houston’s thriving startup ecosystem is supported by a network of experienced leaders who work behind the scenes, investing their time and knowledge to help the next generation of entrepreneurs succeed. Our Mentor of the Year category honors those who dedicate their time and expertise to guide and support budding entrepreneurs. Six individuals have been named finalists for the 2026 award. They support promising startups in the medical tech, digital health, clean energy, hardware sectors and more.

They are: Al Danto, Rice University; Eric Rubenstein, New Climate Ventures; Jeremy Pitts, Activate; Joe Alapat, Liongard; Kyle Judah, Rice University's Liu Idea Lab for Innovation & Entrepreneurship; Rachel Bickham, Bickham Services Unlimited LLC. Read more.

Houston's new state-of-the-art academy FLAMA breaks ground at historic site

Groundbreaking Education

Houston’s newest school for arts and music broke ground in October in the city’s historic East End. The Frank Liu Jr. Academy for Music and Arts (FLAMA), a tuition-free charter school, will welcome students in pre-K through 8th grade next August.

Members of the Liu family, the school’s founding board members, elected officials, and East End community partners gathered at Buffalo Bayou Partnership’s historic Turkey Bend development for the official groundbreaking ceremony on October 8, which kicked off with a performance by the Kinder High School for the Performing and Visual Arts’ Mariachi group.

The new school is on a portion of the former Folgers Coffee Plant, located at 235 N. Norwood St. OMA, an international architectural firm known for its approach to urbanism, cultural projects, and adaptive reuse, is transforming the 1930s plant into a state-of-the-art educational facility.

“We’re excited to celebrate this milestone for FLAMA and look forward to seeing the transformation of the historic Folgers plant into a new home for music and arts education,” said Jason Long, one of the firm’s partners. “Like fine-tuning an instrument, our design recalibrates the existing industrial structure into an open, connected, and expressive environment for learning. FLAMA will be a new learning environment that builds on the character of the existing building while giving it new life for the community.”

Flama academy Courtesy rendering

Unfolding across three stories, the school draws inspiration from Montessori education principles, which prioritize openness, independence, and collective learning through shared “neighborhoods.”

It all begins when students, families and guests enter through a private courtyard. The welcoming space will change the building’s original industrial facade into a brightly colored, kid-friendly spot, complete with yellow and green blocks spelling out the school’s name. The original windows will be restored to preserve the building’s historic character and upgraded to meet contemporary energy standards. Similarly, all of the school’s classrooms are located around the building’s perimeter, providing an abundance of natural light.

Inside, FLAMA’s three stories are divided so that younger students will find their classrooms at the school’s base, and they will move upward through the school as they progress through grade levels. The ground level has a common area for younger kids that could host drum circles, movement classes, or “breakout play.”

Children in first and second grade have their own larger open space, with an eye-catching staircase, that's inspired by the curve of a French horn. The space lends itself to everything from small gatherings to performances by the school’s early musicians.

As students progress through third grade and up, they’ll find FLAMA’s upper floors created to meet their growing artistic and intellectual needs. One example is the open library, a shared spot for students in third through fifth grades. It has flexible furniture that can transform the space into a place for group study and project work, as well as one that can host after-school activities. Directly above this library is a second common room for middle schoolers where students in sixth, seventh, and eighth grades can study.

FLAMA academy Courtesy rendering

These two libraries are connected by an F-shaped floor opening that references both the F-hole of a string instrument and the forte symbol. Musicians know this curly f as a note indicating them to play a passage with strength. That could easily be a metaphor for the school itself, which will combine high-quality education with rigorous academics. This visual cue emphasizes FLAMA’s desire for music and art instruction to amplify learning across reading, writing, math, and science.

“This will be a place where children can discover their talents, families can find opportunities close to home, and music and art can open the doors to a stronger education,” said Congresswoman Sylvia Garcia, who attended the groundbreaking. “I know how much it matters when someone brings opportunity within the reach of a child.”

Dr. R. Scott Allen, FLAMA’s founding superintendent and former principal of Kinder HSPVA, spoke about the school’s vision to pair a rigorous, engaging academic opportunity with deep immersion in music and visual arts.

Congressman Christian Menefee, State Senator Carol Alvarado, and Houston City Councilmember Mario Castillo also delivered remarks at the ceremony, speaking about the school’s power to not only transform Houston’s Second, Third, and Fifth Ward communities, but also bring incredible education opportunities to students. Former Mayor Annise Parker, former State Board of Education Member Staci Childs, State Representative Christina Morales, and Houston City Councilmembers Joaquin Martinez and Sallie Alcorn also attended the event.

“In this city, known for our undeniable contributions to music and arts, the gap has never been ability or talent; it has always been opportunity, and opportunity can be built,” said Kirby Liu, who spoke at the groundbreaking, memorializing his late brother’s vision of arts education for the youngest Houstonians. “When it comes to opportunity being foreclosed on our children, we will try like hell to bust those damned doors down.”

The Frank Liu Jr. Foundation has pledged $20 million in financial support during FLAMA’s first years of operation. Applications are now open for kindergarten and first grade for the 2027-2028 school year.

---

This article first appeared on CultureMap.com.

New manufacturing facility breaks ground at NASA’s Johnson Space Center

making space

HITT Contracting has broken ground on NASA’s Applied Spaceflight Fabrication Facility (ASFF) at Johnson Space Center, the Washington, D.C.-based construction firm announced late last month.

The project, known as Building 70, will house a high-bay machine shop to support component production for future NASA space missions, according to HITT. The 37,625-square-foot building is the first part of a larger goal to create an engineering complex that unites assembly space, lab capabilities and manufacturing at JSC. It will consolidate machining equipment and operations that are currently spread across multiple campus buildings into one location.

The project broke ground in October at JSC’s Historic District. The Houston Business Journal reports construction is expected to wrap in August of 2028.

“This project will modernize facilities that support America’s space missions,” PJ Ross, chief financial officer at HITT, said in a LinkedIn post. “Proud of our team and partners as we begin construction that will advance aerospace testing and innovation.”

HITT Contracting is one of seven companies awarded infrastructure contracts by NASA earlier this year for work at JSC. According to NASA, the construction contracts “[support] up to $300 million in upgrades to mission‑support facilities, utilities, and equipment across the NASA Johnson campus.”

Construction Drive reports that HITT will also renovate Building 13 South on the JSC campus as part of the $300 million initiative.

“Building for precision manufacturing starts with understanding how the space needs to perform,” Todd Hudson, vice president at HITT Contracting, added in the release. “Our team brings the technical expertise and collaborative approach to deliver a facility that meets the Johnson Space Center’s needs today and supports the next generation of spaceflight innovation. We’re proud to continue our partnership with NASA.”

NASA also recently announced awards as part of its expanded Moon Base exploration, science and infrastructure capabilities. Houston-based Intuitive Machines and seven other spacetech companies, including SpaceX, Blue Origin and Firefly Aerospace, were selected to receive funding.

The awards are part of the next phase of NASA’s CLPS (Commercial Lunar Payload Services) initiative, which will grant the companies a combined total of up to $10 billion over 10 years.

Intuitive Machines and Webster-based MEI Technologies were also awarded contracts this past summer from NASA to develop robots for exploring the surface of Mars. Read more here.